Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity.

Signaling Pathways >> Cytoskeleton >> Integrin

Peptides

Research Areas >> Cancer

αvβ3[1]

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3. Cyclo(Arg-Gly-Asp-D-Phe-Val) [c(RGDfV); 35 nM] induces disruption of leukemia cell migration and adhesion to leukemia osteoblasts in the 3D and 2D culture systems, affects the leukemia cell cycle and induces apoptosis in leukemia cells[1].

The osteoblasts are cultured in RPMI 1640 medium for 2 days. MV4-11 cells (1.8×105 cells/mL in the 2D culture system and 1×106 cells/mL in the 3D culture system) are co-cultured with leukemia osteoblasts in RPMI 1640 medium. The experiments used two groups: The experimental group received c(RGDfV) (35 nmol/mL) and the control group received an equal volume of phosphate-buffered saline (PBS) only[1].

[1]. Shen ZH, et al. Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. Oncol Lett. 2016 Nov;12(5):3278-3284.

Cilengitide | Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate salt | Arg-Gly-Asp-Ser | CWHM-12 | OSU-T315 | E 7820 | GLPG 0187 | Firategrast | ATN-161 trifluoroacetate salt | Cucurbitacin B | Eptifibatide acetate salt | iRGD peptide | Lifitegrast | Zaurategrast | Integrin Antagonist 1 (hydrochloride)